Ideaya Biosciences, Servier Dose First Patient in Phase-3 Primary Uveal Melanoma Trial

06:53 AM EDT, 09/09/2026 (MT Newswires) -- Ideaya Biosciences (IDYA) and Servier said Wednesday that the first patient has been dosed in the third phase of the OptimUM-11 trial, evaluating darovasertib in combination with crizotinib for patients with primary uveal melanoma, a rare type of eye cancer. The adjuvant therapy is expected to enroll about 450 patients who have completed local therapy and have an increased risk of developing metastatic disease, they said. The companies said patient eligibility will not depend on Human Leukocyte Antigen status and will be randomized 1:1 to receive darovasertib with crizotinib for 12 months or observation. The trial's primary endpoint is relapse-free survival, the companies said. Ideaya holds regulatory and commercial rights to darovasertib in the United States, while Servier holds all such rights outside the United States, they added. The companies said OptimUM-11 is being conducted as a registrational study and will share development costs for the trial.